WOGI did reduce their authorized shares from 5B to 1B and cancelled 2B of their common shares so they have provided a good model for RT to follow in one respect.

Why didn't you sell a lot more of your RLFTF?

I feel pretty sure DonDonDonDon that you are speaking from your own experience here which is always good for personal focusing but doesn't always apply elsewhere.

That is what happens when the EUA is announced.

Of course it matters. It is going down very slowly in a failing attempt to panic weak hands. Why? The weak hands left long ago.

Are you saying you would react the same if the SP was dropping on high volume? It is low volume now because the major holders don't want give up a lot of shares hoping to get a big drop. It is unlikely they can achieve that now so they would lose shares instead of being able to get more at a lower price.

A check on volume in the past few weeks indicates hardly anyone is selling at this point.

Yes, and Javitt also pointed out they have a great team and have added to it by bringing people with Big Pharma experience in what they are doing. He said they know what they are doing and are committed to doing it. When the host said so its Small Pharma against Big Pharma, Javitt said we are also
Smart Pharma.

We do have to admit there are some odd things going on here. The FDA is the primary organization that has to be satisfied. I have a feeling that the leaders of RT, NeroRx, Gem and BRPA have a pretty good idea as to when and how that will happen. I feel it will be fairly soon. In the meantime, these terrific guys, Dr. Javitt, RAM, etc., who know what is a stake for patients with COVID also don't mind picking up every share they can especially if it is at the expense of weak hands ("Oh ye of little faith"). Since they know big things are coming they may as well give hints that there may be problems in this quickly put together consortium of companies. Who cares if the faithless sell? Since they have to wait a bit for developments, they may as well do what they can to get as many valuable shares as they can.

If so, I don't blame them. In fact, I take it as a good sign. At this point, though, I do think it is a fading game. Almost all the weak hands have already moved along. Anyone still here is holding strong. Major selling would only happen on confirmed very bad news and I don't think that is at all in the cards anymore. Like Javitt, RAM and the rest we will keep Waiting for Godot and it ain't gonna be that long of a wait.

Many seem to not know what is happening in India.

Tiger Money is too far gone into his nonsense about this mythical manipulation to steal RLF100 from RT by using a different name or a slight change to formula. Ain't gonna happen.

OK, now I see this on Aviptadil research in India. Do you know how far along the research is? And if Aviiptadil treatment has been going well there is it likely the Indian govt. will soon be authorizing wide use of Aviptadil given the incredible crisis they have on their hands?

I see no reference in the link to Aviptadil being used in India. Where do you see it?

Could Zyesami be next (or soon) in India?

++++++++++++++++++++++++++++++++++++++

Antiviral Granted Emergency Approval to Treat Moderate COVID-19 Adult Patients in India

April 24, 2021 - 2:48 pm CDT - Coronavirus Today

India-based Zydus Cadila announced that the company had received Restricted Emergency Use Approval from the Drug Controller General of India to use ‘Virafin,’ Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.

When a single-dose subcutaneous regimen is administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, said the company's press statement issued on April 23, 2021.

In the multicentric phase 3 trial conducted in 20-25 centers across India, Virafin had shown the lesser need for supplemental oxygen, clearly indicating that it could control respiratory distress and failure, which has been one of the major challenges in treating COVID-19.

The Phase III trials demonstrated that a higher proportion of patients in the PegIFN arm showed a two-point statistically significant clinical improvement (WHO 7-point ORDINAL SCALE) on day 8 as compared to the Standard of Care (SOC arm) (80.36% vs. 68.18%).

Speaking on the development, Dr. Sharvil Patel, Managing Director, Cadila Healthcare Limited, commented, “The fact that we can offer a therapy which significantly reduces the viral load when given early on can help in better disease management. It comes at a much-needed time for patients, and we will continue to provide them access to critical therapies in this battle against COVID-19.”

Virafin will be available on the prescription of a medical specialist for use in a hospital / institutional setup in India.

Zydus Cadila is a leading Indian pharmaceutical company located in Ahmedabad and is a fully integrated, global healthcare provider.

—Staff Review
Medical Review byDanielle Reiter, RN

Right now nothing will bring significantly more attention to Aviptadil (Zyesami; RLF-100) than getting the EUA. And we already know that even Fauci and other important people in the COVID effort know about Zyesami. Once the EUA comes through money will start coming in and then the powers that be with Zyesami can start developing a real long term marketing team. They don't have the resources to do that right now and, in any case, the most important force at play right now is the FDA which does not pay attention to marketing efforts. Their resources and efforts currently need to be directed at the FDA and the trial results.

It seems absurd to me to think that Javitt is trying to eliminate Relief in some way.

Good points here.

I have seen many comments on Amarin and Vascepa but hadn't looked closely at it.

Certainly, in the long run, if good results continue, it will benefit from relationships with Harvard and Kaiser Permanente.

UK coronavirus contracts raise corruption alarm, report warns
A probe of nearly 1,000 contracts in response to the crisis found a bias towards politically connected companies.

https://www.politico.eu/article/report-uk-coronavirus-contracts-costing-3-6b-raise-alarm-of-corruption/

The VIP herein is not Vasoactive.

Nothing in this article relates directly to Lenzilumab. Also, what about the bradykinin storm?

Clinical trial of therapeutics for severely ill hospitalized COVID-19 patients begins
Patients with acute respiratory failure may now enroll in NIH-sponsored trial.
"It could open new understanding into the repair of damaged lungs following ARDS.”

https://www.nih.gov/news-events/news-releases/clinical-trial-therapeutics-severely-ill-hospitalized-covid-19-patients-begins#.YIGCIeEERSU.twitter

I take it TFF does not have a big enough PR program.

I am going to speculate on this issue for a moment. I think NeuroRx has a lot of the data analyzed and it is showing very good things but they don't have all of it done (possibly important issues about lung radiographs and x-rays, etc.). Is it not the case that if they gave what they have to Relief it would be substantial enough that Relief would have to release it. NeuroRx is not obligated to release the data they have. They may want all the data in place and fully analyzed before it is released. They may feel that even with very good data in place the full and comprehensive analysis will be even better. NeuroRx may also want to be further along in establishing how things are going to be worked out for the various partners in this venture. Having all of these things in much better shape (i.e. a NASDAQ listing, etc.) would allow a much better stock market response to the announcement of an EUA.

The controversy over the lousy $4M may be cover for Relief and NeuroRx to fight a bit over leverage on how several of these things ultimately get worked out.

Mapping Severe COVID-19 in the Lungs at Single-Cell Resolution

https://directorsblog.nih.gov/2021/04/13/mapping-severe-covid-19-in-the-lungs-at-single-cell-resolution/

This fits the bill.

I have to doubt this issue would be out in the public if they weren't pretty sure they have incredible results. Results of the study, if they are top notch, will count much more than these spats as long as they work it out fairly quickly.

If there is manipulation going on it is likely happening so that the big investors can grab even more shares.

If a tremendous amount of earnings is at stake they will resolve it quickly.

I doubt these issues would be coming out if the various powers that be didn't think there is a tremendous amount at stake which in the longer run is a good thing for investors.

Vaccine Nationalism Will Boost Covid-19 Treatments Like $RLFTF's ZYESAMI™
Vaccine treatments that have been shown to lower mortality should be given as rollouts in addition to vaccines.

https://lastfuturist.com/vaccine-nationalism-will-boost-covid-19-treatments-like-rlftfs-zyesami/

A lot of speculation here, Tiger, with minimal real knowledge.

That would be fine with me. But, again, if someone posts stupid stuff I may go after them.

Good news here.

Both J&J and Astrazeneca have blood clotting issues.

Post all the articles you want about ultra-violet light being used against COVID.

Trump is not only a fool, he launched a treasonous insurrection against our country in which a security officer was killed and Trump's supporters were literally shitting and pissing in the hallways of our Capitol building.

This is the same guy he claimed he was making America respected around the world.

Bleach is a disinfectant. Lysol, Clorox and bleach have been used to indicate how stupid and ignorant his statement about disinfectant was. It is truly amazing you can't see what an idiot Trump is.

The J&J problems should enhance the chances for Zyesami given the well documented safety of synthetic VIP.